Production of Chloroplast-Derived Plague Vaccines Antigens

Introduction

Plague is one of the world's deadliest human diseases caused by the Gram-negative bacterium Yersinia pestis, including bubonic plague, pneumonic plague, and septicemic plague. The most common of these is bubonic plague. Once this bacteria enters the lymph nodes, it can cause the lymph nodes to swell and form lumps. Due to the hazard of plague, it has been listed as one of the class A biological agents. Despite years of extensive research worldwide, there is no safe and effective vaccine against the plague. Chloroplast engineering for the production of vaccines and biopharmaceuticals has ushered in a new era of biotechnology, and a variety of oral vaccine antigens have been expressed in chloroplasts, such as the cholera toxin B subunit of vibrio cholerae, Bacillus anthracis protective antigen, Clostridium tetani TetC, canine parvovirus 2L21 peptide, etc. These advances open the door to the development of orally administrable plague vaccine antigens.

Fig. 1. Picture of plague vaccine and plague bacteria Yersinia pestis display.

Solutions

Our engineers are passionate about engineering chloroplasts to produce edible vaccines to help control human and animal disease. Lifeasible is an expert in vaccine research and development, with a variety of mature and comprehensive platforms and technologies, providing global customers with professional solutions for the production of chloroplast-derived plague vaccines. Our engineers successfully used two defined antigens capable of eliciting high levels of protection, the outer capsule level 1 (F1) and the low calcium responsive V (LcrV or V) proteins. Here, we successfully developed a proven platform for the production of plague subunit vaccines in transgenic tobacco chloroplasts. Our strategy is as follows:

(1) The F1-V fusion gene was cloned into the universal chloroplast vector pLD-CtV to construct the pLDS-F1V vector.
(2) Tobacco chloroplast transformation by particle bombardment of the vector. The aadA gene, which also confers mycin resistance, was used for selection.
(3) Distinguish true chloroplast transformants from nuclear transformants and mutants by PCR analysis.
(4) Analysis by PCR and Southern blot to ensure the integration of the F1-V fusion gene.
(5) Western blot was used to detect the expression of F1-V protein in transgenic tobacco.
(6) Inoculate animals with plague vaccine.

Features of Our Solutions

• Safe and effective without human pathogen contamination.
• Minimize processing time and costs.
• Maintain its functions stably from production, transportation, storage to delivery to the mainframe.
• Tobacco grows fast, enabling rapid mass production of plague vaccines.
• F1-V levels in chloroplasts are capable of delivering sufficient vaccine antigens in intact plant cells.

Chloroplast-transformed oral plague vaccines are safe and effective, and have important implications for protecting humans or animals from plague bacteria Yersinia pestis. Lifeasible has extensive knowledge and experience in the development and production processes of chloroplast-derived plague vaccines. Our mission is to provide customers with comprehensive, reliable, professional solutions to accelerate your research. If you are interested in our solutions for the production of chloroplast-derived plague vaccines, please contact us at any time.

References

1. Arlen P A, Singleton M, Adamovicz J J, et al. (2008) Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts[J]. Infection and immunity. 76(8): 3640-3650.
2. Verma S K, Tuteja U. (2016) Plague vaccine development: current research and future trends[J]. Frontiers in immunology. 7: 602.